Skip to main content
ENZN
OTC Life Sciences

Enzon Files S-4 for Merger with Viskase, Proposing 1-for-100 Reverse Stock Split and Significant Dilution for Existing Common Shareholders

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$0.066
Mkt Cap
$4.898M
52W Low
$0.031
52W High
$0.219
Market data snapshot near publication time

summarizeSummary

Enzon filed an S-4 for its merger with Viskase, detailing a 1-for-100 reverse stock split and significant dilution for existing common shareholders, who will own ~5.1% of the combined entity, while Icahn-affiliated parties will hold ~93.32%.


check_boxKey Events

  • Merger with Viskase Companies, Inc.

    Enzon will merge with Viskase, with Viskase surviving as a wholly-owned subsidiary and the combined entity operating as "Viskase Holdings, Inc.".

  • Extreme Dilution for Existing Common Stockholders

    Current Enzon common stockholders are projected to own approximately 5.1% of the combined company post-merger.

  • 1-for-100 Reverse Stock Split Proposed

    A reverse stock split is planned immediately prior to the merger, reducing the number of outstanding shares.

  • Series C Preferred Stock Exchange Offer

    Enzon is offering to exchange all Series C Preferred Stock for common stock, a condition for the merger. Icahn Enterprises Holdings L.P. (IEH Parties) have already agreed to exchange their 98.2% stake.


auto_awesomeAnalysis

Enzon Pharmaceuticals, an acquisition vehicle, has filed a comprehensive S-4 registration statement detailing its proposed merger with Viskase Companies, Inc. The transaction is highly transformative, with existing Enzon common stockholders expected to own only approximately 5.1% of the combined entity, which will be renamed "Viskase Holdings, Inc." This significant dilution is coupled with a proposed 1-for-100 reverse stock split of Enzon's common stock. The merger is also contingent on an exchange offer for Enzon's Series C Preferred Stock, largely held by Icahn Enterprises Holdings L.P. (IEH Parties), who will ultimately control approximately 93.32% of the combined company. Viskase has faced material financial deterioration and a "going concern" qualification, making this merger a critical event for its survival, while for Enzon, it represents a complete change in business and capital structure. The overwhelming control by IEH Parties post-merger means minority shareholders will have very limited influence.

At the time of this filing, ENZN was trading at $0.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.9M. The 52-week trading range was $0.03 to $0.22. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ENZN - Latest Insights

ENZN
Mar 27, 2026, 7:48 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
ENZN
Mar 26, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
9
ENZN
Mar 25, 2026, 8:38 AM EDT
Filing Type: 425
Importance Score:
7
ENZN
Mar 25, 2026, 8:36 AM EDT
Filing Type: 8-K
Importance Score:
7
ENZN
Mar 24, 2026, 8:35 AM EDT
Filing Type: SC TO-I/A
Importance Score:
8
ENZN
Mar 24, 2026, 8:30 AM EDT
Filing Type: 425
Importance Score:
8
ENZN
Mar 24, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
ENZN
Mar 19, 2026, 4:07 PM EDT
Filing Type: SC TO-I/A
Importance Score:
7
ENZN
Mar 16, 2026, 4:10 PM EDT
Filing Type: 425
Importance Score:
7
ENZN
Mar 11, 2026, 8:36 AM EDT
Filing Type: 425
Importance Score:
7